Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
NPC Blog
NPC Blog
2010 Archives
2009 Archives
2008 Archives
2007 Archives
2006 Archives
Search Archives
Archives
  • December 2012 (3)
  • November 2012 (1)
  • October 2012 (1)
  • May 2012 (1)
  • December 2011 (1)
  • November 2011 (3)
  • October 2011 (4)
  • September 2011 (4)
  • August 2011 (6)
  • July 2011 (13)
  • June 2011 (8)
  • May 2011 (10)
  • April 2011 (14)
  • March 2011 (6)
  • February 2011 (2)
  • February 2010 (4)
  • January 2010 (1)
  • December 2009 (1)
  • November 2009 (1)
  • October 2009 (1)
  • September 2009 (2)
  • July 2009 (1)
  • April 2009 (1)
  • March 2009 (1)
  • February 2009 (1)
  • December 2008 (1)
  • October 2008 (1)
  • September 2008 (1)
  • August 2008 (2)
  • July 2008 (2)
  • June 2008 (4)
  • May 2008 (1)
  • April 2008 (1)
  • March 2008 (4)
  • February 2008 (1)
  • April 2007 (1)
  • December 2006 (1)
  • October 2006 (1)
  • September 2006 (1)
  • July 2006 (2)
  • June 2006 (3)
  •  

    Subscribe in a reader

    E-Alerts
    Signup to receive news and announcements from Nutra Pharma:
    First Name:
    Last Name:
    Email:
    Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.
    NPC Blog

    Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™

    Posted on May 2nd, 2012 by Rik Deitsch

    Nutra Pharma announces the roll-out of a two-level, on-line affiliate sales and marketing plan for the sales and distribution of their Nyloxin™ line of pain relievers.

    May 2, 2012Coral Springs, Florida — Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that LWR Partners, their outside branding and marketing firm, has begun their on-line affiliate sales and marketing program to aid in the promotion, branding and distribution of Nyloxin™. Click here to read more.


    SEC Disclaimer
    This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


    del.icio.us:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ digg:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ spurl:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ wists:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ simpy:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ newsvine:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ blinklist:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ furl:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ reddit:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ fark:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ blogmarks:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ Y!:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ smarking:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ magnolia:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ segnalo:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™ gifttagging:Nutra Pharma Begins Affiliate Sales & Marketing Program for the Distribution of Nyloxin™

     


    Nutra Pharma Letter to Shareholders

    Posted on Dec 20th, 2011 by Rik J. Deitsch

    Nutra Pharma CEO, Rik J Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company.

    December 19, 2011Coral Springs, Florida — Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company’s Chief Executive Officer, Rik J Deitsch, had published a Shareholder Letter on the Company’s website.

    “We have been very busy here at Nutra Pharma,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “I wanted to take this opportunity to outline the progress that we’ve made and the timeline for our future efforts moving into 2012 and beyond,” he concluded.

    Nutra Pharma currently produces three drugs for the treatment of pain: Cobroxin®, an over-the-counter pain reliever designed to treat moderate to severe (Stage 2) chronic pain; as well as Nyloxin™ and Nyloxin™ Extra Strength, stronger versions of Cobroxin®. These products are currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress.

    Click here to download the letter


    SEC Disclaimer
    This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Nutra Pharma Letter to Shareholders", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


    del.icio.us:Nutra Pharma Letter to Shareholders digg:Nutra Pharma Letter to Shareholders spurl:Nutra Pharma Letter to Shareholders wists:Nutra Pharma Letter to Shareholders simpy:Nutra Pharma Letter to Shareholders newsvine:Nutra Pharma Letter to Shareholders blinklist:Nutra Pharma Letter to Shareholders furl:Nutra Pharma Letter to Shareholders reddit:Nutra Pharma Letter to Shareholders fark:Nutra Pharma Letter to Shareholders blogmarks:Nutra Pharma Letter to Shareholders Y!:Nutra Pharma Letter to Shareholders smarking:Nutra Pharma Letter to Shareholders magnolia:Nutra Pharma Letter to Shareholders segnalo:Nutra Pharma Letter to Shareholders gifttagging:Nutra Pharma Letter to Shareholders

     


    Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain

    Posted on Nov 30th, 2011 by Corporate Communications

    Nutra Pharma announces the publication of their study outlining the mechanism of action of their pain drugs to be published in the journal Neuropharmacology.

    November 30, 2011Coral Springs, Florida — Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain. Read on…


    SEC Disclaimer
    This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


    del.icio.us:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain digg:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain spurl:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain wists:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain simpy:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain newsvine:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain blinklist:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain furl:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain reddit:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain fark:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain blogmarks:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain Y!:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain smarking:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain magnolia:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain segnalo:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain gifttagging:Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain

     


    Incredible Offer on Cobroxin!

    Posted on Nov 17th, 2011 by Corporate Communications

    SAVE!

    on the first over-the-counter pain reliever clinically proven to treat various levels of chronic pain.

    Specially formulated for arthritis, lower back pain, shoulder pain,migraines, and neuralgia.

    Now Only $10.99

    Regular Price $25.99
    And, when you purchase the Cobroxin Gel, you will get the Oral Spray for free, that’s a total savings of $21.00!

    Just use Coupon Code: NP11 at checkout

    Plus, take advantage of Free Ground Shipping (in the USA) until December 31, 2011.

    BUY NOW

     


    SEC Disclaimer
    This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Incredible Offer on Cobroxin!", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


    del.icio.us:Incredible Offer on Cobroxin! digg:Incredible Offer on Cobroxin! spurl:Incredible Offer on Cobroxin! wists:Incredible Offer on Cobroxin! simpy:Incredible Offer on Cobroxin! newsvine:Incredible Offer on Cobroxin! blinklist:Incredible Offer on Cobroxin! furl:Incredible Offer on Cobroxin! reddit:Incredible Offer on Cobroxin! fark:Incredible Offer on Cobroxin! blogmarks:Incredible Offer on Cobroxin! Y!:Incredible Offer on Cobroxin! smarking:Incredible Offer on Cobroxin! magnolia:Incredible Offer on Cobroxin! segnalo:Incredible Offer on Cobroxin! gifttagging:Incredible Offer on Cobroxin!

     


    Season’s Greeting with Free Shipping on Nyloxin

    Posted on Nov 16th, 2011 by Corporate Communications

    Your friends at Nutra Pharma Corp. wish you a Pain-Free Holiday Season with FREE Ground Shipping on any purchase on Nyloxin.com over $40.00

    www.nyloxin.com
    Free ground shipping within the USA expires December 31, 2011.

     


    SEC Disclaimer
    This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Season’s Greeting with Free Shipping on Nyloxin", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


    del.icio.us:Season's Greeting with Free Shipping on Nyloxin digg:Season's Greeting with Free Shipping on Nyloxin spurl:Season's Greeting with Free Shipping on Nyloxin wists:Season's Greeting with Free Shipping on Nyloxin simpy:Season's Greeting with Free Shipping on Nyloxin newsvine:Season's Greeting with Free Shipping on Nyloxin blinklist:Season's Greeting with Free Shipping on Nyloxin furl:Season's Greeting with Free Shipping on Nyloxin reddit:Season's Greeting with Free Shipping on Nyloxin fark:Season's Greeting with Free Shipping on Nyloxin blogmarks:Season's Greeting with Free Shipping on Nyloxin Y!:Season's Greeting with Free Shipping on Nyloxin smarking:Season's Greeting with Free Shipping on Nyloxin magnolia:Season's Greeting with Free Shipping on Nyloxin segnalo:Season's Greeting with Free Shipping on Nyloxin gifttagging:Season's Greeting with Free Shipping on Nyloxin

     


    « Newer Posts - Older Posts »

     
    Quick Nav
    Nyloxin // Chronic Pain Relief
    Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
     

     

     
    Recent News
     
    August 03, 2017
    New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy


    June 21, 2017
    Nutra Pharma Announcing Launch of Luxury Feet


    June 07, 2017
    Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


     
     
    Announcements
    Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
     
     
    Facebook   Twitter
     
    NPC
    Privacy Policy Code of Ethics